Circulating Fibroblast Growth Factor-21 and Risk of Metachronous Colorectal Adenoma
Authors:
- 12 September 2020
- journal article
- research article
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52 (3) , 940-946
Abstract
Purpose Prior work has shown that higher circulating concentrations of fibroblast growth factor-21 (FGF-21) are associated with an increased likelihood of developing colorectal cancer. We conducted a prospective study to assess the relationship between circulating FGF-21 and odds of developing early neoplastic lesions in the colorectum. Methods A total of 94 study participants were included from the ursodeoxycholic acid (UDCA) trial, a phase III, randomized, double-blind, placebo-controlled clinical trial of the effect of 8–10 mg/kg of body weight UDCA vs. placebo. Logistic regression analyses were conducted to evaluate the association between baseline FGF-21 concentrations and odds of developing a metachronous adenoma. Results Of the characteristics compared across tertiles of FGF-21 concentrations, including age, race, sex, BMI, and other variables, only a previous personal history of colorectal polyps prior to entry into the UDCA trial was statistically significantly related to FGF-21 levels, with a proportion of 26.7%, 56.7%, and 50.0% across the first, second, and third tertiles, respectively (p < 0.05). Higher circulating concentrations of FGF-21 were statistically significantly associated with greater odds of developing a metachronous colorectal adenoma. After adjusting for potential confounders and when compared with the lowest tertile of FGF-21, the adjusted ORs (95% CIs) for metachronous colorectal adenoma in the second and third tertiles were 4.72 (95% CI, 1.42–15.72) and 3.82 (95% CI, 1.15–12.68), respectively (p trend < 0.05). Conclusion Our results reveal for the first time that, in addition to a recently discovered association with colorectal cancer, circulating FGF-21 concentrations are significantly and directly associated with odds of developing metachronous colorectal adenoma.Keywords
Funding Information
- National Cancer Institute (RO1CA140285, P01CA041108, P30CA023074)
This publication has 23 references indexed in Scilit:
- Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stressBMC Gastroenterology, 2013
- Trends in Overall and Cause-Specific Mortality Among Patients With Inflammatory Bowel Disease From 1982 to 2010Clinical Gastroenterology and Hepatology, 2013
- Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trialThe Lancet, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trialsThe Lancet, 2010
- Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and diseaseCell and tissue research, 2010
- Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor‐21 in patients with type 2 diabetes and obesityClinical Endocrinology, 2009
- Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin ResistanceDiabetes Care, 2009
- Colorectal Cancer: Epidemiology, Risk Factors, and Health ServicesClinics in Colon and Rectal Surgery, 2005
- Phase III Trial of Ursodeoxycholic Acid To Prevent Colorectal Adenoma RecurrenceJNCI: Journal of the National Cancer Institute, 2005